{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:26:16Z","timestamp":1792121176725,"version":"4.4.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013209","name":"Hellenic Foundation for Research and Innovation","doi-asserted-by":"publisher","award":["HFRI-26473"],"award-info":[{"award-number":["HFRI-26473"]}],"id":[{"id":"10.13039\/501100013209","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.coi.2026.102749","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:57:40Z","timestamp":1773161860000},"page":"102749","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Current role of ATG in GVHD prevention: optimizing post-transplantation outcomes through combination with PTCY"],"prefix":"10.1016","volume":"100","author":[{"given":"Maria","family":"Liga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Tsokanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeliki N","family":"Georgopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3097-2532","authenticated-orcid":false,"given":"Alexandros","family":"Spyridonidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2026.102749_sbref1","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","article-title":"Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial","volume":"10","author":"Finke","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coi.2026.102749_bib2","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/S2352-3026(19)30220-0","volume":"7","author":"Walker","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.coi.2026.102749_sbref3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1506002","article-title":"Antilymphocyte globulin for prevention of chronic graft-versus-host disease","volume":"374","author":"Kr\u00f6ger","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102749_bib4","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1200\/JCO.20.00150","article-title":"Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: a multicenter, open-label, randomized controlled study","volume":"38","author":"Chang","year":"2020","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.coi.2026.102749_bib5","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/bmt.2016.272","article-title":"Low-dose alemtuzumab for GvHD prevention followed by prophylactic donor lymphocyte infusions in high-risk leukemia","volume":"52","author":"Tsirigotis","year":"2017","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.coi.2026.102749_bib6","first-page":"154","article-title":"Allogeneic stem cell transplantation with CD34+ cell selection","volume":"1","author":"Roldan","year":"2019","journal-title":"Clin Hematol Int"},{"key":"10.1016\/j.coi.2026.102749_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines5030035","article-title":"Role of \u03b1\u03b2 T cell depletion in prevention of graft versus host disease","volume":"5","author":"Abdelhakim","year":"2017","journal-title":"Biomedicines"},{"key":"10.1016\/j.coi.2026.102749_bib8","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","article-title":"Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"7","author":"Penack","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.coi.2026.102749_bib9","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2017.75.8177","article-title":"Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation","volume":"35","author":"Soiffer","year":"2017","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.coi.2026.102749_bib10","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S2352-3026(17)30029-7","article-title":"Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis","volume":"4","author":"Admiraal","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.coi.2026.102749_bib11","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1182\/blood-2015-02-627786","article-title":"Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102749_sbref12","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl"},{"key":"10.1016\/j.coi.2026.102749_bib13","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1182\/blood-2017-01-761627","article-title":"How much immunosuppression do we need?","volume":"129","author":"Spyridonidis","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102749_sbref14","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1182\/blood-2016-09-737825","article-title":"Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide","volume":"129","author":"Kanakry","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102749_bib15","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.bbmt.2015.06.006","article-title":"Influence of stem cell source on outcomes of allogeneic reduced-intensity conditioning therapy transplants using haploidentical related donors","volume":"21","author":"Bradstock","year":"2015","journal-title":"Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl"},{"key":"10.1016\/j.coi.2026.102749_bib16","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2016-06-723205","article-title":"Posttransplantation cyclophosphamide and sirolimus for prevention of GVHD after HLA-matched PBSC transplantation","volume":"128","author":"Greco","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102749_sbref17","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102749_sbref18","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/bloodadvances.2021005847","article-title":"Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial","volume":"6","author":"Broers","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.coi.2026.102749_sbref19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJMoa2503189","article-title":"Graft-versus-host disease prophylaxis with cyclophosphamide and cyclosporin","volume":"393","author":"Curtis","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102749_sbref20","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/bloodadvances.2022007026","article-title":"Posttransplantation cyclophosphamide expands functional myeloid-derived suppressor cells and indirectly influences tregs","volume":"7","author":"Fletcher","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.coi.2026.102749_bib21","first-page":"782.e1","volume":"27","author":"Arcuri","year":"2021","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.coi.2026.102749_bib22","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1002\/ajh.27343","volume":"99","author":"Devillier","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.coi.2026.102749_bib23","article-title":"Bone marrow graft versus peripheral blood graft in haploidentical hematopoietic stem cells transplantation: a retrospective analysis in\u00a01344 patients of SFGM-TC registry","volume":"17","author":"Lacan","year":"2024","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"10.1016\/j.coi.2026.102749_bib24","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.clml.2020.04.003","article-title":"Impact of adding antithymocyte globulin to posttransplantation cyclophosphamide in haploidentical stem-cell transplantation","volume":"20","author":"El-Cheikh","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.coi.2026.102749_bib25","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.4049\/jimmunol.2000578","article-title":"Posttransplant cyclophosphamide and antithymocyte globulin versus posttransplant cyclophosphamide as graft-versus-host disease prophylaxis for peripheral blood stem cell haploidentical transplants: comparison of T cell and NK effector reconstitution","volume":"205","author":"Makanga","year":"2020","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2026.102749_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11041106","article-title":"Addition of a single low dose of anti T-lymphocyte globulin to post-transplant cyclophosphamide after allogeneic hematopoietic stem cell transplant: a pilot study","volume":"11","author":"Xue","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.coi.2026.102749_bib27","first-page":"587.e1","volume":"28","author":"Battipaglia","year":"2022","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.coi.2026.102749_bib28","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/bjh.18483","volume":"200","author":"Zhang","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.coi.2026.102749_bib29","first-page":"32.e1","article-title":"Combination of anti-thymocyte globulin with post-transplant cyclophosphamide for GVHD prophylaxis in patients undergoing haploidentical hematopoietic stem cell transplantation: systematic review and meta-analysis","volume":"31","author":"Luo","year":"2025","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.coi.2026.102749_sbref30","first-page":"536.e1","article-title":"Outcomes of antithymocyte globulin-post-transplantation cyclophosphamide-cyclosporine-based versus antithymocyte globulin-based prophylaxis for 10\/10 HLA-matched unrelated donor allogeneic hematopoietic cell transplantation","volume":"30","author":"Salas","year":"2024","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.coi.2026.102749_sbref31","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-198798","article-title":"A randomized pilot trial comparing anti-thymocyte globulin (ATG) with ATG plus post transplant cyclophosphamide (PTCy) for prophylaxis against acute and chronic graft versus host disease (GVHD) in matched donor hematopoietic cell transplants (HCT)","volume":"144","author":"Walker","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102749_sbref32","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/s41409-022-01816-1","article-title":"Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT","volume":"57","author":"Spyridonidis","year":"2022","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.coi.2026.102749_sbref33","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1182\/bloodadvances.2024014781","article-title":"PTCy-based graft-versus-host disease prophylaxis for matched sibling donor allogeneic hematopoietic cell transplantation","volume":"9","author":"Desai","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.coi.2026.102749_bib34","doi-asserted-by":"crossref","DOI":"10.1177\/0963689720965900","article-title":"Post-transplant cyclophosphamide and thymoglobulin, a graft-versus-host disease prophylaxis in matched sibling donor peripheral blood stem cell transplantations","volume":"29","author":"Kunacheewa","year":"2020","journal-title":"Cell Transpl"},{"key":"10.1016\/j.coi.2026.102749_bib35","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.20.03502","article-title":"National Marrow Donor Program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide","volume":"39","author":"Shaw","year":"2021","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.coi.2026.102749_sbref36","article-title":"Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis after mismatched unrelated donor peripheral blood stem cell transplantation","volume":"43","author":"Al Malki","year":"2025","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.coi.2026.102749_bib37","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41409-025-02514-4","article-title":"The impact of individual comorbidities in transplant recipients receiving post-transplant cyclophosphamide","volume":"60","author":"Spyridonidis","year":"2025","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.coi.2026.102749_bib38","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jcyt.2021.06.003","article-title":"A biomarker-guided, prospective, phase 2 trial of pre-emptive graft-versus-host disease therapy using anti-thymocyte globulin","volume":"23","author":"Khanolkar","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.coi.2026.102749_bib39","doi-asserted-by":"crossref","first-page":"6098","DOI":"10.1182\/bloodadvances.2020003336","article-title":"Biomarker-guided preemption of steroid-refractory graft-versus-host disease with \u03b1-1-antitrypsin","volume":"4","author":"Gergoudis","year":"2020","journal-title":"Blood Adv"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526000269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526000269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T04:20:34Z","timestamp":1779510034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791526000269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":39,"alternative-id":["S0952791526000269"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2026.102749","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current role of ATG in GVHD prevention: optimizing post-transplantation outcomes through combination with PTCY","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2026.102749","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102749"}}